Multi Pronged Study Adds to Body of Evidence for Baby Colic Kaneka’s Infant Probiotic Formulation
Pasadena, TX (April 19 2022) – Kaneka Probiotics has announced the publication of a new study examining the effects of a formulation of two probiotic strains on functional gastrointestinal disorder s FGID The formulation which consists of Bifidobacterium longum subsp. longum KABP ™ 042 and Pediococcus pentosaceus KABP ™ 041 strains (and which will be referred to herein as the “KABP Formulation”) was also evaluated for its safety and mechanisms of action in the GI system including intestinal barrier integrity. Based on the findings of the study, the researchers demonstrated that the KABP Formulation significantly reduces the severity of FGID such as colic and constipation Interestingly, in addition of the observation in the infants their parents experienced favorable result s on anxiety Scientists estimate that one in two infants develop FGID during the first 6 months of life, and the most prevalent manifestations of FGID are infant colic and functional constipation. The microbiota of infants with FGID are altered and contribute to the condition characterized as a gut brain axis disorder.
The study, published in Frontier of Microbiology, examines the effects of the KABP Formulation through multiple investigations including in silico analyses, in vitro characterization, and an in vivo trial on infants with FGID. In the in vivo portion of the study, 34 infants were administered the liquid probiotic drops for 14 weeks. The university researchers from Spain and Pediatric Primary Care in Italy demonstrated that the KABP Formulation reduced FGID severity and also provided confirmation of its safety. As there are many factors involved in the pathophysiology of FGIDs, the researchers also evaluated the effects of B. longum KABP™-042 and P. pentosaceus KABP™-041 upon infants of different feeding modes (breast-fed as well as formula-fed), as well as different delivery types (vaginally delivered or C-section). Amazingly, the benefits of the KABP Formulation were realized regardless of the feeding mode or delivery mode.1
“This newly published study substantiates the efficacy of the KABP Formulation for reducing FGIDs which is one of the most prevalent challenges for infant s and a significant source of anxiety for parents Moreover, the study substantiates the efficacy of Floradapt Baby Colic, our dietary supplement probiotic that is constituted entirely of the KABP Formulation” explained Mike Kolifrath, Vice President, Sales and Marketing of the Probiotics Division at Kaneka. “Although Baby Colic is a dietary supplement and is not intended to diagnose, treat, cure or prevent any disease, this multi pronged study of the effects of the KABP Formulation adds another layer of support to the existing competent and reliable scientific evidence that Baby Colic supports a calm gut and healthy microflora in babies and helps reduce the duration of crying episodes and crying time Kaneka’s robust presence in infant probiotic nutrition has again been proven,” Kolifrath added.
About Kaneka
Floradapt Baby Colic is part of the Kaneka Probiotics Portfolio, which are products based on a mechanistic approach to identify optimal strains for specific health applications. Our strain library collection has over 1,000+ strains strategically sourced from populations around the world with conserved microbiomes. The Kaneka Probiotics portfolio includes formulations for Immune, Upper Respiratory Tract, Digestion, GI Challenges, Oral Gum Health, Colic, Women’s, Gut Brain Axis, Cardiovascular, and Stress/Mood/Anxiety. We are committed to quality, innovation science and have 20+ studies that are ongoing for areas in Sports Nutrition, Leaky Gut, Nutrition Absorption, Migraine Halitosis, and many other disciplines
1 Asto, E, et al, Probiotic Properties of Bifidobacterium longum KABP042 and Pediococcus pentosaceus KABP041 Show Potential to Counteract Functional Gastrointestinal Disorders in an Observational Pilot Trial in Infants. Front. Microbiol., 12 January 2022 | https://doi.org/10.3389/fmicb.2021.741391
